ZLAB Zai Lab Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZLAB

Price (delayed)

$18.86

Market cap

$1.87B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.5

Enterprise value

$1.18B

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To ...

Highlights
Zai Lab's revenue has increased by 26% YoY and by 9% from the previous quarter
ZLAB's gross profit is up by 21% year-on-year and by 7% since the previous quarter
The quick ratio is down by 46% year-on-year
The equity has contracted by 24% YoY and by 4.3% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.zailaboratory.com
Peers: OPK OPTN

Key stats

What are the main financial stats of ZLAB
Market
Shares outstanding
99.21M
Market cap
$1.87B
Enterprise value
$1.18B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.45
Price to sales (P/S)
6.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.07
Earnings
Revenue
$291.07M
EBIT
-$338.83M
EBITDA
-$321.14M
Free cash flow
-$209.77M
Per share
EPS
-$3.5
Free cash flow per share
-$2.16
Book value per share
$7.68
Revenue per share
$2.99
TBVPS
$10
Balance sheet
Total assets
$988.44M
Total liabilities
$226.27M
Debt
$63.35M
Equity
$762.17M
Working capital
$696.53M
Liquidity
Debt to equity
0.08
Current ratio
4.63
Quick ratio
4.3
Net debt/EBITDA
2.14
Margins
EBITDA margin
-110.3%
Gross margin
62.9%
Net margin
-116.4%
Operating margin
-121%
Efficiency
Return on assets
-32.5%
Return on equity
-40.2%
Return on invested capital
-334.3%
Return on capital employed
-42.5%
Return on sales
-116.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZLAB stock price

How has the Zai Lab stock price performed over time
Intraday
-0.05%
1 week
1.07%
1 month
4.95%
1 year
-39.22%
YTD
-30.99%
QTD
8.83%

Financial performance

How have Zai Lab's revenue and profit performed over time
Revenue
$291.07M
Gross profit
$182.97M
Operating income
-$352.23M
Net income
-$338.95M
Gross margin
62.9%
Net margin
-116.4%
The net margin has grown by 34% YoY and by 7% from the previous quarter
The company's operating margin rose by 27% YoY and by 10% QoQ
Zai Lab's revenue has increased by 26% YoY and by 9% from the previous quarter
ZLAB's gross profit is up by 21% year-on-year and by 7% since the previous quarter

Growth

What is Zai Lab's growth rate over time

Valuation

What is Zai Lab stock price valuation
P/E
N/A
P/B
2.45
P/S
6.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.07
The EPS has grown by 17% YoY
The stock's P/B is 55% below its 5-year quarterly average of 5.5 and 12% below its last 4 quarters average of 2.8
The equity has contracted by 24% YoY and by 4.3% from the previous quarter
ZLAB's price to sales (P/S) is 92% lower than its 5-year quarterly average of 84.1 and 27% lower than its last 4 quarters average of 8.7
Zai Lab's revenue has increased by 26% YoY and by 9% from the previous quarter

Efficiency

How efficient is Zai Lab business performance
Zai Lab's return on invested capital has shrunk by 79% YoY and by 22% QoQ
The ROS has grown by 34% YoY and by 7% from the previous quarter
ZLAB's ROE is down by 8% QoQ and by 7% YoY
The ROA has contracted by 6% from the previous quarter

Dividends

What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZLAB.

Financial health

How did Zai Lab financials performed over time
The quick ratio is down by 46% year-on-year
The current ratio has contracted by 46% YoY
The debt is 92% less than the equity
The equity has contracted by 24% YoY and by 4.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.